Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the United States and is projected to maintain a substantial market lead over ritlecitinib.
In his interview, Dr. Amin discusses his views on the FDA’s recent approval of ritlecitinib for the treatment of adolescent patients with alopecia areata.
1. Patients in the ritlecitinib group showed significant improvements in alopecia symptoms, with Severity of Alopecia Tool (SALT) scores ≤ 20, compared to placebo. 2. Adverse events between groups were comparable; there were no reported deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Alopecia areata is an autoimmune form of hair loss that affects both children